In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic behavior, the
Categories
Biotech
Moderna raises over $600-million through IPO, falls below IPO price
Biotech company Moderna raised above $600 million on Thursday by selling about 26 million of its common stock at $23 a share,
Takeda Pharmaceutical, Shire get shareholders’ nod for $62-billion deal
Takeda Pharmaceutical and Shire Plc announced that their shareholders have approved the $62 billion merger transaction. Takeda said that at least 88%
Arena Pharmaceuticals soars on the $1.2 billion deal with United Therapeutics
Arena Pharmaceuticals (ARNA) inked a deal with United Therapeutics (UTHR) to sell and develop its Phase 3 investigational drug candidate ralinepag worldwide.
Amarin turns positive after Citi upgrade and CEO’s clarification on REDUCE-IT study
Amarin Corporation (AMRN) shares turned to green Wednesday after they were battered out in the last two days following the data presented
Celgene plunges to new 52-week low despite beating Q3 estimates
Celgene Corp. (CELG) reported better-than-expected profit and revenue numbers for the third quarter of 2018 on strong product sales. Revenue climbed 18%
Proteostasis Therapeutics stock skyrockets on positive trial results
Clinical stage biopharma company Proteostasis Therapeutics (PTI) announced positive preliminary results from a Phase 1 study for the treatment of cystic fibrosis
Amarin shares pump up on positive results from cardiovascular study
Amarin Corporation (AMRN) announced positive results from a clinical study in which Vascepa, an EPA drug, was used to treat about 8,200
New drug sales power Amgen’s Q2 results
In the midst of Amgen (AMGN) facing intense competition for its blockbuster products from its rivals, the pharma company posted better-than-expected second-quarter
Celgene – a sweet or sour pill?
It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time do some
Celgene’s potential blockbuster drug filing fails to pass the muster with the FDA
U.S. Food and Drug Administration (FDA) has sent a "Refuse to file" letter to Celgene with regards to the New Drug Application